Eye surgery – Web Xpress http://web-xpress.com/ Mon, 29 Nov 2021 14:09:18 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://web-xpress.com/wp-content/uploads/2021/10/icon-9-150x150.png Eye surgery – Web Xpress http://web-xpress.com/ 32 32 LensGen® Receives US FDA IDE Approval to Begin Clinical Study of Juvene® Presbyopia Correction Intraocular Lens https://web-xpress.com/lensgen-receives-us-fda-ide-approval-to-begin-clinical-study-of-juvene-presbyopia-correction-intraocular-lens/ Mon, 29 Nov 2021 13:30:00 +0000 https://web-xpress.com/lensgen-receives-us-fda-ide-approval-to-begin-clinical-study-of-juvene-presbyopia-correction-intraocular-lens/ The LensGen Juvene IOL is designed to permanently restore clear, continuous vision at all distances, including near and intermediate. The lens is modular and has a fluid optical component that changes shape to adjust focus on demand of today’s active lifestyles, from viewing mobile devices and computer screens to high quality far vision in a […]]]>

The LensGen Juvene IOL is designed to permanently restore clear, continuous vision at all distances, including near and intermediate. The lens is modular and has a fluid optical component that changes shape to adjust focus on demand of today’s active lifestyles, from viewing mobile devices and computer screens to high quality far vision in a wide range of lighting conditions. The lens is implanted using the same surgical techniques used with traditional intraocular lenses.

“We are proud to have taken this important milestone for the company, which allows us to move forward with the IDE pivotal trial with the ultimate goal of obtaining pre-market approval in the larger market of eye care to the world, ”said Ramgopal rao, CEO of LensGen. “Obtaining IDE approval for a new device is a tremendous undertaking and a tremendous accomplishment for the company, and we are grateful to the FDA for their rigorous and insightful advice throughout the process.”

“Based on the clinical data from the Grail study and my direct experience of surgery and observations of patients implanted with Juvene IOL, LensGen technology has the potential to provide a significant and superior new option to our patients,” said declared Eric Donnenfeld, MD, clinical professor in the ophthalmology department of the New York University Grossman School of Medicine and founding partner of Ophthalmic Consultants of Long Island.

LensGen is currently in the process of raising Series B funding which is expected to close in the first half of 2022.

ABOUT LENSGEN

LensGen, Inc., is a privately held ophthalmic medical device company that develops cutting-edge technologies to improve the vision and lives of patients. Through its pioneering efforts to develop a versatile capsule-filling intraocular lens platform and fluid lens that mimics the natural human lens, the company aims to restore youthful vision to millions of cataract and presbyopia patients through worldwide.

ABOUT CATARACTS

A cataract is a cloudy area in the natural lens of the eye that affects vision. As cataracts develop, the lens of the eye gradually becomes hard and cloudy, allowing less light to pass through, making it harder to see. Cataracts are the most common age-related eye disease and the leading cause of preventable blindness.1 Over four million cataract surgeries are performed annually in the United States and are expected to grow over 16% by the end of 2024. The market for presbyopia correcting IOLs is expected to grow 60% by the end from 2024.2

ABOUT PRESBYTY

Presbyopia is a common age-related eye condition in which people find it difficult to focus on things up close. It involves the gradual loss of the eye’s ability to focus on nearby objects, such as smartphones, computers, books, and menus. Everyone will experience presbyopia as they get older, with symptoms often first appearing when a person enters their 40s and continues to worsen into their 60s.3 In the United States, an estimated 112 million people suffer from vision problems due to presbyopia.4

Warning: investigation device. Limited by the federal government (or United States) for investigative use.

The references

1. Centers for Disease Control and Prevention, Vision Health Initiatives. Available at: https://www.cdc.gov/visionhealth/basic/ced/index.html

2. Scope of the market. 2019 IOL Market Report
3. Mayo Clinic, Presbyopia. Available at: https://www.mayoclinic.org/diseases-conditions/presbyopia/symptoms-causes/syc-20363328.
4. American Association of Optometry: Optometric Clinical Practice Guidelines, Care of the Presbyopic Patient. Available at: https://www.aoa.org/documents/optometrists/CPG-17.pdf

Contact: Geline Atienza
Lensgen, Inc.
(949) 382-1308
[email protected]

SOURCE Lensgen

Related links

www.lensgen.com


Source link

]]>
Portsmouth man arrested after London Road assault leaves woman in need of urgent eye surgery with serious facial injuries https://web-xpress.com/portsmouth-man-arrested-after-london-road-assault-leaves-woman-in-need-of-urgent-eye-surgery-with-serious-facial-injuries/ Thu, 25 Nov 2021 13:43:00 +0000 https://web-xpress.com/portsmouth-man-arrested-after-london-road-assault-leaves-woman-in-need-of-urgent-eye-surgery-with-serious-facial-injuries/ The assault took place between 10:15 p.m. and 11:30 p.m. on Saturday, November 20, when a woman was assaulted in London Road, near the intersection of Chichester Road. The woman fell to the ground and was punched in the face, suffering from a ruptured left eye, a fractured eye socket, a fractured cheekbone and a […]]]>

The assault took place between 10:15 p.m. and 11:30 p.m. on Saturday, November 20, when a woman was assaulted in London Road, near the intersection of Chichester Road.

The woman fell to the ground and was punched in the face, suffering from a ruptured left eye, a fractured eye socket, a fractured cheekbone and a deep laceration in the eye. the back of the head.

She was taken to Queen Alexandra Hospital for urgent eye surgery.

Register now to our daily newsletter

Newsletter cut through the noise

Police are investigating an assault in North End that left a woman in need of urgent eye surgery. Image bank: Habibur Rahman

Read more

Read more

A Portsmouth man has been fined nearly £ 2,000 after being caught ‘leaving his girlfriend’s house …

A 46-year-old man from Portsmouth has been arrested on suspicion of grievous bodily harm with intent and remains in detention.

Officers believe several members of the public witnessed the incident and rushed to help the woman while she was on the ground, according to a Hampshire Police spokesperson.

He said: “We are calling on these witnesses to come forward and provide us with information that could aid the investigation.

“Were you around at the time? Did you see the incident? Do you have any CCTV footage or dash camera footage that could help our investigations? “

Anyone with information regarding the incident is asked to call the police on 101 and give the reference number 44210472091.

A message from the editor, Mark Waldron

You can subscribe here for unlimited access to our online coverage, including Pompey, for 26p per day.


Source link

]]>
STRYPER frontman MICHAEL SWEET forced to cancel solo Christmas show due to surgery for protruding retina https://web-xpress.com/stryper-frontman-michael-sweet-forced-to-cancel-solo-christmas-show-due-to-surgery-for-protruding-retina/ Tue, 23 Nov 2021 13:31:13 +0000 https://web-xpress.com/stryper-frontman-michael-sweet-forced-to-cancel-solo-christmas-show-due-to-surgery-for-protruding-retina/ Stryper frontman Michael Sweet has checked in with the following update: “I just saw the ophthalmologist and I have a retinal detachment. I will need emergency surgery (vitrectomy) on my right eye. A lot of time has passed (a long story and many details) so I may or may not have normal vision I think […]]]>

Stryper frontman Michael Sweet has checked in with the following update:

“I just saw the ophthalmologist and I have a retinal detachment. I will need emergency surgery (vitrectomy) on my right eye. A lot of time has passed (a long story and many details) so I may or may not have normal vision I think I will and of course I welcome any prayers I can receive.

My left eye (good eye) has an old retinal tear and will require a laser (at the office) to be repaired. It is also sensitive to retinal detachment.

I will be down for the account for 2 weeks (lying face down so the bubble they place in my eye can stay in place) and I guess that will be the hardest part of it all.

The doctor says it’s hereditary.

The Christmas show is canceled but tickets will be honored next year as we have rescheduled the show for 12/10/2022. My sincere apologies because it breaks my heart to cancel a show or event. I love you all and deeply appreciate all concerns, thoughts and prayers. “

Stryper recently made the following announcement:

“We’ve made our two special recorded concert videos, recorded live at SpiritHouse, which you can now watch as often as you like with a purchase of each stream. So far, we’ve released Even The Devil Believes and To Hell With The Diable, and soon the soldiers under command are heading to our Veeps page and buy one or both to get those lifetime views. “

Stryper recently launched an official website for their upcoming official documentary with the following message:

“Have you signed up yet? This is the official Stryper documentary. Directed by the people who were there including fan stories and all of your favorite songs. Sign up to receive the newsletter to stay up to date on how that you can be a part of. “

The website includes a page where fans can share their band-related stories with Stryper. Go to StryperDocumentary.com for updates and to participate.


Source link

]]>
pandemic travel Travel insurance nightmare: $ 38,000 medical bill rejected https://web-xpress.com/pandemic-travel-travel-insurance-nightmare-38000-medical-bill-rejected/ Sun, 21 Nov 2021 11:15:47 +0000 https://web-xpress.com/pandemic-travel-travel-insurance-nightmare-38000-medical-bill-rejected/ Duy Hoa Tran, a retired Vietnamese schoolteacher, arrived at Los Angeles in February 2020 visiting her 2 month old daughter and grandson. Two weeks later the door closed behind him. To prevent the spread of COVID-19, Vietnam close its borders. No commercial flights would be allowed in the country for the next 18 months. Tran’s […]]]>

Duy Hoa Tran, a retired Vietnamese schoolteacher, arrived at Los Angeles in February 2020 visiting her 2 month old daughter and grandson. Two weeks later the door closed behind him. To prevent the spread of COVID-19, Vietnam close its borders. No commercial flights would be allowed in the country for the next 18 months.

Tran’s daughter, An Tran, who has a doctorate in business administration and teaches marketing at the University of La Verne, did what she felt was necessary to provide medical coverage for her then 65-year-old father during the pandemic. But the only option for a visitor with a tourist visa was travel insurance. In the beginning march 2020, An Tran found and bought a font for about $ 350 a month, from a company called Seven Corners.

She might as well not have cared.

The elder Tran had stayed in An’s house in Diamond bar about a year ago when he told his daughter he was having trouble seeing with her right eye. A visit to an ophthalmologist produced a solemn verdict: Tran suffered from severe glaucoma and would quickly go blind unless he had an operation.

Seven Corners has given written pre-approval for the procedures recommended by Dr. Brian Chen. To be sure, An Tran called the insurer “several times” to confirm that he would cover the expenses, but no one she spoke with would give her a definitive answer, she said. Chen, however, assured An that insurance companies generally covered the treatment, which was quite common.

At April 19, Tran underwent the first of three eye surgeries to resolve glaucoma. The surgeries – the last one was on July 19 – They succeeded. And then on 5 August, Seven Corners sent An Tran a denial of service letter.

The company’s policy excluded coverage for any “pre-existing condition”, that is, any condition “whether or not it is.

previously not manifested, symptomatic, known, diagnosed, treated or disclosed, ”the letter reads.

An Tran and her father were hooked for nearly $ 38,000 in medical bills, although Seven Corners pre-authorized the surgery and paid around $ 6,000 for insurance during the previous year and a half.

As for the bill, “My dad obviously can’t pay it,” Tran said. His $ 260 the monthly pension from the Vietnamese government is not enough for him to live in Vietnam, she said.

Surgical acts Duy Hoa Tran received are quite common in United Statessaid Dr. Davinder Grover, ophthalmologist in the Dallas zone and clinical spokesperson for the American Academy of Ophthalmology.

Medicare would typically pay about a quarter of the $ 37,896.83 Tran was billed for the surgeries, Grover said. If Tran’s daughter had known in advance that the insurance would not cover the procedures, the doctor’s office might have been willing to bill something like $ 12,000, he said.

The policy underwritten by An Tran had no deductible and provided coverage for up to $ 100,000 in medical bills, including COVID-19 care. But travel insurance usually only covers emergency or urgent medical expenses, depending on the California state insurance commission, which regulates policies in the state.

Megan Moncrief, marketing director for Squaremouth, which bundles travel insurance plans from various companies – including some from Seven Corners – and offers them through its website, said the language of the policy was not unusual for insurance trip. She noted the policy stipulation that it only covered certain acute conditions if the patient sought treatment within 24 hours of the first symptoms.

Moncrief said that the fact that Tran did not seek immediate treatment could be the reason his surgeries were not covered. (Seven Corners declined to comment on the case.) She admitted that it was hardly surprising that he didn’t rush to the doctor at the first sign of discomfort: “I don’t know if I am. wouldn’t have done that either if I had blurry vision. “

As for Seven Corners’ refusal to pay despite pre-certification, that’s not uncommon, she said. By pre-certifying, the insurer verifies that a procedure is a covered benefit but does not guarantee that the insurer will cover it for that particular patient.

Travel insurance generally offers little protection for any health problem related to a pre-existing condition, whether that condition has already been diagnosed, says Susan yates, general manager of the we for Falck Global Assistance, an international insurer.

“For visitors to the we, especially those who are not permanent residents or citizens, it can be difficult to get health insurance, ”she said. The Affordable Care Act does not cover tourists, although some resident non-citizens may purchase coverage.

“It is generally better for a visitor to purchase travel insurance in their home country, but in some countries (Vietnam being a), the insurance market is not developed, ”Yates wrote in an email.

Tran had tried unsuccessfully for months to return home to his town near Ho Chi Minh City, where his wife lives with another grandchild. On 14 occasions, An bought her tickets on scheduled commercial flights which were later canceled. He was also unable to secure a seat on charter flights organized by the Vietnamese government; these tickets were generally only available through third parties charging up to $ 10,000.

Eye surgeon Chen offered to discuss the case with KHN, but his medical group’s lawyer said it was his policy not to discuss insurance issues with reporters, even with consent. of the patient.

After KHN approached him to discuss the matter, Chen told An Tran that he was giving up his $ 8,144 fees for surgeries. The Acuity Eye group, where he practices, did not immediately confirm Chen’s offer, but told An Tran that he was also seeking clearances to waive his fees and all other charges.

At September 15th, Duy Hoa Tran finally managed to take a charter flight to return Vietnam. He is happy to be home, An Tran said.

Under California subsidiary liability laws, it could be responsible for its remaining bills.

Kaiser Santé news is a national newsroom that produces in-depth journalism on health issues. Along with policy analysis and polls, KHN is one of KFF’s three main operational programs (Kaiser Family Foundation). KFF is an endowed nonprofit organization that provides information on health issues to the nation.


Source link

]]>
EyePoint Pharmaceuticals Announces $ 115.4 Close https://web-xpress.com/eyepoint-pharmaceuticals-announces-115-4-close/ Fri, 19 Nov 2021 17:32:50 +0000 https://web-xpress.com/eyepoint-pharmaceuticals-announces-115-4-close/ WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company engaged in the development and commercialization of therapeutics to help improve the lives of patients with severe eye disorders , today announced the closing of the previously announced public offering of 5,122,273 common shares, which included the full exercise […]]]>

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company engaged in the development and commercialization of therapeutics to help improve the lives of patients with severe eye disorders , today announced the closing of the previously announced public offering of 5,122,273 common shares, which included the full exercise by the underwriters of their option to purchase an additional 1,095,000 common shares, and warrants pre-funded subscription plans to purchase up to a total of 3,272,727 common shares. The common shares were sold at a public offering price of $ 13.75 per share, and the pre-funded warrants were sold at a purchase price of $ 13.74 per pre-funded warrant, for proceeds. total gross of approximately $ 115.4 million, before deducting subscription discounts. and commissions and other offering charges payable by EyePoint. All titles were sold by EyePoint.

Cowen and Guggenheim Securities acted as co-book managers for the offer. Cantor acted as the passive book manager for the offering.

EyePoint intends to use the net proceeds of the offering to advance EYP-1901 into and through Phase 2 clinical trials for wet AMD, DR and RVO, as well as to support its development initiatives. pipeline at an early stage, and for general business purposes.

The securities described above have been offered by the Company in accordance with a prior registration statement on Form S-3 (No. 333-258598) previously filed with the Securities and Exchange Commission (SEC) on August 6, 2021 and declared effective by the SEC on August 11, 2021.

The securities have been offered by means of a prospectus supplement and an accompanying prospectus relating to the offering which form part of the registration statement. A final prospectus supplement relating to and describing the terms of the offer was filed with the SEC on November 18, 2021 and is available on the SEC’s website at www.sec.gov. Copies of the Final Prospectus Supplement and accompanying prospectus relating to the offering can be obtained from Cowen and Company, LLC, c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department , by phone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com, Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by phone at (212) 518 -9544, or by email to GSEquityProspectusDelivery @ guggenheimpartners.com, or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th floor, New York, NY 10022; Email: prospectus@cantor.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described in this document, and there will be no sale of such securities in any state or jurisdiction in which such offering, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company engaged in the development and commercialization of therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for prolonged intraocular drug delivery, including EYP-1901, a potential half-yearly anti-intravitreal anti-VEGF therapy initially targeting age-related wet macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following eye surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent that the statements made in this press release deal with information which is not historical, they are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements include: but not limited to statements regarding the use of the proceeds of the offering and other statements identified by words such as “will”, “potential”, “could “,” Can “,” believe “,” intend “,” continue “,” “plans”, “expects”, “anticipates”, “estimates”, “may”, other words of similar meaning or the use of future dates. Forward-looking statements, by their nature, deal with matters that are, to varying degrees, uncertain. Uncertainties and risks could cause EyePoint’s actual results to differ materially from those expressed or implied by EyePoint’s forward-looking statements. For EyePoint, this includes stock price volatility and financial market uncertainties, the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy, and the impact general commercial and economic conditions. More detailed information on these and other factors that could affect EyePoint’s actual results are described in the documents filed by EyePoint with the SEC, including its annual report on Form 10-K for the year ended 31. December 2020, as revised or supplemented by its quarterly reports. on Form 10-Q and other documents filed with the SEC. All forward-looking statements contained in this press release speak only as of the date of this press release. EyePoint assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investors:
Christina tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media contact
Amy phillips
Green room communications
Direct: 412-327-9499
aphillips@greenroompr.com


Source link

]]>
Go through my heart and hope to die, or stick a needle in my eye? https://web-xpress.com/go-through-my-heart-and-hope-to-die-or-stick-a-needle-in-my-eye/ Wed, 17 Nov 2021 17:45:30 +0000 https://web-xpress.com/go-through-my-heart-and-hope-to-die-or-stick-a-needle-in-my-eye/ November 17, 2021 1 min read Biography / Disclosures Published by: Biography: Hovanesian is a faculty member at UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Disclosures: Hovanesian does not report any relevant financial disclosure. ADD A SUBJECT TO E-MAIL ALERTS Receive an email when new […]]]>

November 17, 2021

1 min read

Biography: Hovanesian is a faculty member at UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Disclosures: Hovanesian does not report any relevant financial disclosure.


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact customerservice@slakinc.com.

In this issue’s cover story of Ocular Surgery News, we explore emerging treatments for the subset of age-related dry macular degeneration patients with geographic atrophy.

Although this condition affects many more patients than wet AMD – and this number is likely to increase – there are at least three factors that make the treatment of geographic atrophy (GA) different from that of the wet form of this condition. sickness.

1. Patients with GA are harder to find. With wet AMD, most patients are already followed by a retinal specialist and receive treatment by injection. It is easy to take advantage of this population of emerging treatments as they are already seen at least four times a year. In contrast, many patients with GA do not see an ophthalmologist at all, or if they do, their general ophthalmologist or optometrist might be reluctant to refer them to a retinal specialist.

John A. Hovanesian

2. Patients with GA are less motivated. The untreated rate of visual loss in patients with wet AMD is rapid and impossible to ignore. Patients are extremely motivated to avoid progression. Injection therapy, while unpleasant, is accepted even on a monthly basis for nearly a million Americans. In comparison, visual loss with GA is much more insidious, decreasing vision perhaps by one line per year. And the benefit of injecting drugs, according to current studies, can take 6 months or more. Unfortunately, many of these elderly patients with GA will “go through their hearts and hope to die” rather than allowing a doctor to “stick a needle” in their eye.

3. Our best hope is to catch the GA sooner. If we can better identify patients whose first signs of AMD are precursors of GA, these new treatments could be life-changing. Preventing progression to 20/30 is much more exciting than doing it to 20/100. Genetics and other risk stratification efforts may soon help us identify patients at an earlier age, perhaps around the time of cataract surgery, where one can imagine he might one day become the standard of care for performing a risk analysis for the future development of GA.

The availability of revolutionary treatments for GA should generate a lot of enthusiasm in our specialty. While reality may limit their rapid growth, we owe it to patients to find the best candidates and prevent life-changing vision loss as early as possible.


Source link

]]>
Clinical challenges: gene therapy for inherited retinal diseases https://web-xpress.com/clinical-challenges-gene-therapy-for-inherited-retinal-diseases/ Mon, 15 Nov 2021 16:30:37 +0000 https://web-xpress.com/clinical-challenges-gene-therapy-for-inherited-retinal-diseases/ FDA approval of voretigene neparvovec (Luxturna) for the treatment of patients with confirmed biallelism RPE65 Almost 4 years ago, mutation-associated retinal dystrophy marked a turning point in gene therapy. Since then, clinicians have witnessed the positive impact gene therapy has had on the lives of patients and their families. “Luxturna dramatically improves retinal sensitivity, which […]]]>

FDA approval of voretigene neparvovec (Luxturna) for the treatment of patients with confirmed biallelism RPE65 Almost 4 years ago, mutation-associated retinal dystrophy marked a turning point in gene therapy.

Since then, clinicians have witnessed the positive impact gene therapy has had on the lives of patients and their families.

“Luxturna dramatically improves retinal sensitivity, which results in improved night vision in most patients and even visual acuity in some patients,” said Mark Pennesi, MD, PhD, of the Casey Eye Institute Ophthalmic Genetic Clinic of Oregon Health & Science University in Portland, in an interview.

“It is fascinating to hear which changes in real life are the most significant for patients,” said Christina Weng, MD, of Baylor College of Medicine in Houston. MedPage today. Weng recalled how thrilled the family of a 5-year-old boy with Leber’s congenital amaurosis (ACL) type 2 was after the treatment, “when he was able to participate in Halloween for the first time in his life.” .

With one dose per eye, voretigene neparvovec has the ability to “target the source of the disease, and potentially permanently stop or dramatically reduce disease progression from an early age in eligible patients,” noted Cynthia X. Qian, MDCM, of the University of Montreal, who is a member of the Canadian Ophthalmological Society and the Canadian Retinal Society.

The subretinal gene therapy trials began with the discovery of RPE65 variants and the role of biallelic RPE65 gene mutations in rare types of retinitis pigmentosa and in ACL, the incidence of which is estimated to be two to three per 100,000 people, and accounts for 5% of all hereditary retinal diseases (RDI) diagnosed.

Clinical signs of early DRI, such as nystagmus, decreased visual acuity, and poor night vision or dark adaptation, should prompt further testing, Pennesi said. MedPage today. “Ultimately, genetic testing is absolutely essential in determining the etiology of the disease and whether there might be any treatments (approved or experimental).”

In addition, “ancillary tests – particularly optical coherence tomography (OCT), electroretinography, and fundus autofluorescence – can be very useful in providing additional information, as there may be heterogeneous phenotypes for the exact same mutation, ”Weng noted.

RPE65-the associated IRD causes a loss of visual function in two components: “a blockage of the visual cycle which is reversible with gene therapy and a cellular degenerative process which is unlikely to be reversible in its terminal stages”, according to an opinion. The indication of voretigene neparvovec requires the presence of “viable retinal cells”.

However, the evaluation of photoreceptor health using OCT on human RPE65 genetic mutants did not clearly relate the degree of loss of visual function to age and characteristics of OCT such as outer nuclear layer thickness. Thus, the identification of patients likely to respond to gene therapy is left to the discretion of the treatment provider, the review suggested.

Advances in subretinal delivery of gene therapy include the use of more sophisticated vectors to deliver the transgene into the host cell and nucleus, Weng said. MedPage today. “Today, we have the ability to modify viral vectors via rational design or directed evolution to confer an enhanced transduction, tropism and / or immunogenicity profile. There are also non-vector options today. viral, such as nanoparticles or iontophoresis. “

“Second, improvements in the surgical approach and instrumentation make subretinal childbirth very safe and efficient,” Weng added. “Likewise, the Orbit subretinal delivery system, which provides access to the subretinal space externally from the suprachoroidal space, rather than transvitreally, is being evaluated. for certain types of gene therapy. This approach would potentially avoid some of the risks associated with pars plana vitrectomy. “

The most common potential side effects with voretigene neparvovec are associated with the surgery needed to inject the gene therapy: redness of the eyes, transient blurring, and acute inflammation, Weng said, which usually go away within days to weeks.

“The rarer side effects – most related to surgery rather than the gene therapy itself – include infection, macular hole, retinal detachment, high intraocular pressure, cataract formation, vision loss, posterior inflammation and retinal pigment changes, “she continued. .

Perifoveal atrophy is a known risk after subretinal injection of voretigene neparvovec, Qian noted. While longer term studies are needed, “what we know so far is that it appears to occur in the months following subretinal injection and is intimately linked to the area. injection. injection site. “

“There are only preliminary reports in a small cohort of patients and even many of these patients still reported overall functional improvement,” Pennesi said. “A larger retrospective study of all patients is needed to determine the true prevalence.”

In addition to voretigene neparvovec, “University College London, the University of Nantes and the University of Florida are among some of the institutions which are all working independently on the improvement and adjustment of their developed gene product in order to improve AAV2 targeting [adeno-associated virus 2] vector, maximize protein expression of the gene product, while keeping the risk of intraocular inflammation low, ”said Qian MedPage today. “AGTC and MeiraGTx / Janssen have completed Phase I / II trials using their respective viral vectors with positive results. MeiraGTx / Janssen is also entering phase III trials to investigate the use of an optimized version of their AAV to deliver the gene product. “

“Previous phase I studies of QLT091001 showed that oral supplementation with 9-cis-retinyl acetate instead of the missing 11-cis-retinal resulted in improved visual acuity, visual field and MRI functions in enrolled patients, ”a added Qian. “This suggests that oral supplementation with synthetics may bypass the blockage of the retinoid cycle and promote the continuation of the phototransduction cascade, and may also be a promising avenue of exploration in the future. Beyond ACV 2 and RPE65 gene mutations, in response to the challenge of treating autosomal dominant diseases with excess gene product, exciting new findings, such as gene editing, CRISPR / Cas9, RNA therapy and optogenetic neuromodulation are also evolving rapidly and add new tools to the arsenal of therapies to treat RDI.

  • Kate Kneisel is a freelance medical journalist based in Belleville, Ontario.

Disclosures

Pennesi said he worked as a consultant for Allergan Retina, Biogen / Nightstar and REGENXBIO, and Spark Therapeutics.

Weng revealed his relationships with Alcon, Alimera Sciences, Allergan / AbbVie, the Dutch Ophthalmic Research Center, Novartis, Regeneron and REGENXBIO.

Qian said he worked as a consultant for Allergan, Bayer, Novartis and Roche.


Source link

]]>
Mfon Ekpa Foundation performs eye surgery on 300 displaced people in FCT – Blueprint Newspapers Limited https://web-xpress.com/mfon-ekpa-foundation-performs-eye-surgery-on-300-displaced-people-in-fct-blueprint-newspapers-limited/ Wed, 10 Nov 2021 19:55:24 +0000 https://web-xpress.com/mfon-ekpa-foundation-performs-eye-surgery-on-300-displaced-people-in-fct-blueprint-newspapers-limited/ The Mfon Ekpa Foundation (MEF) in collaboration with Pro-Health International launched a medical awareness program aimed at performing 300 surgical treatments for internally displaced persons (IDPs) in the village of Wasa, in the territory of the federal capital (FCT) Abuja. Pro-Health International lead consultant Dr Iko Ibanga explained that the outreach program was in honor […]]]>

The Mfon Ekpa Foundation (MEF) in collaboration with Pro-Health International launched a medical awareness program aimed at performing 300 surgical treatments for internally displaced persons (IDPs) in the village of Wasa, in the territory of the federal capital (FCT) Abuja.

Pro-Health International lead consultant Dr Iko Ibanga explained that the outreach program was in honor of Mfon Ekpa, the late son of Dr Anthonia Ekpa, Permanent Secretary of the Federal Ministry of Special Functions and Intergovernmental Affairs , adding that the program was also a celebration of the life of the late Mfon Ekpa.

“It’s a celebration of the life of a young man who had so much potential, which made an impact on what we do for health. He helped us design a lot of things. So, being his first birthday in Heaven, we thought we should celebrate it in a way that we reach out to people and bring them to life.

“Those who need surgery, we take them to three hospitals in the city. So that’s a third of what’s going on. The goal is that in this week we will do 300 surgeries, ranging from eye surgeries, general surgeries, genocological surgeries and dental surgeries, ”he said.

Giving an overview of the program, the Permanent Secretary of the Federal Ministry of Special Functions and Intergovernmental Affairs Ms Anthonia Akpabio Ekpa said her son left for heaven about two months ago and the awareness was marked to celebrate his birthday. “I personally know that he had great thoughts for today and one of those thoughts was to give back to God through the poor and needy.

“Today is his first birthday in Heaven, and we want to continue to remember that day while he’s here on earth, and do whatever we think he would have been happy to do. , this is just the first start for us, Mfon Ekpa Foundation (MEF), we want to continue this and we are lucky to have a family in Pro-Santé that Mfon has been so involved in. So Pro-Health International is a channel through which we reach out and I am happy ”.

In addition, the camp president Geoffrey Bitrus praised the foundation, said medicine, food and clothing are completely free.

Wasa IDP camp secretary John Samela said a total of 5,128 people are currently living in the camp with many urgent needs including medicine, clothing and food. Therefore, the awareness brought immense happiness to the camp.

“We are happy because it has been a long time since we had such visitors. We are grateful because the doctors came when most of our children were not feeling well. You can see them testing and treating our people for various diseases, ”he said.

No tags for this post. No tags for this post.


Source link

]]>
Overview of the Global Vitrectomy Devices Market to 2028 https://web-xpress.com/overview-of-the-global-vitrectomy-devices-market-to-2028/ Mon, 08 Nov 2021 18:45:00 +0000 https://web-xpress.com/overview-of-the-global-vitrectomy-devices-market-to-2028/ DUBLIN, November 8, 2021 / PRNewswire / – The Vitrectomy Devices Market Size, Share and Trend Analysis Report by Product, by Application (Diabetic Retinopathy, Retinal Detachment), by End Use (Hospitals, Outpatient Surgery Centers), by Region and segment forecast, 2021-2028 ” report was added to ResearchAndMarkets.com offer. Research and Markets logo The global vitrectomy devices market […]]]>

DUBLIN, November 8, 2021 / PRNewswire / – The Vitrectomy Devices Market Size, Share and Trend Analysis Report by Product, by Application (Diabetic Retinopathy, Retinal Detachment), by End Use (Hospitals, Outpatient Surgery Centers), by Region and segment forecast, 2021-2028 ” report was added to ResearchAndMarkets.com offer.

Research and Markets logo

The global vitrectomy devices market size is expected to reach $ 1.7 billion by 2028. The market is expected to grow at a CAGR of 6.2% from 2021 to 2028. The increasing prevalence of diabetes is expected to drive the likelihood of diabetic retinopathy, thereby contributing to the growth of the market. Moreover, the growing demand for vitrectomy due to its associated advantages to provide support for other eye surgeries is also expected to drive the market growth.

Ophthalmic diseases are common in the elderly. The growing geriatric population is expected to drive the market and the need for vitrectomy devices. According to the National Institute on Aging (NIA), the elderly population is expected to reach 72.0 million people by 2030, which could lead to the prevalence of ophthalmic disorders. In addition to this, an increasing number of hospital admissions for retinal surgeries such as vitrectomy is expected to drive the market growth. Additionally, hospitals have also installed vitrectomy devices to improve vitreoretinal surgery procedures.

COVID-19 is expected to negatively impact the market in 2020. This is due to reduced medical visits for eye care to prevent the spread of infection. Additionally, people with COVID must experience ophthalmic issues like conjunctivitis, which in turn prevent healthcare professionals from performing general eye surgeries. However, the development of government guidelines to provide constant and efficient medical care including ophthalmology could boost the market growth during the forecast period.

The risks associated with Vitrectomy are also expected to hamper the growth of the market. The patient who has undergone a vitrectomy has a high probability of generating a cataract after a few years, which has a negative impact on its adoption. In addition, the lack of professional ophthalmologists to understand how advanced vitrectomy devices with multiple functionality work can also pose a threat to the market.

Highlights of Vitrectomy Devices Market Report

  • Vitrectomy machines held the largest share of revenue in 2020 due to the development of advanced machines with features like small gauge size and intraocular pressure control.

  • Vitrectomy Packs segment is expected to grow at the fastest rate during the forecast period owing to its increasing adoption for various indications

  • Retinal Detachment Applications segment is expected to grow at the fastest rate during the forecast period due to the increasing prevalence of high myopia. Patients with high myopia have a greater likelihood of developing retinal detachment

  • Outpatient Surgery Centers Segment is Expected to Show Highest Growth Rate During Forecast Period Due to Lower Costs and Shorter Wait Time

  • In Asia Pacific, the market is expected to grow at the highest rate due to the maximum number of diabetic retinopathy cases in the region and the presence of a large pool of patients

Main topics covered:

Chapter 1. Methodology and scope

Chapter 2. Executive summary

Chapter 3. Variables, Trends and Scope of Vitrectomy Devices Market
3.1. Market lineage outlook
3.1.1. Parents Market Outlook
3.1.2. Related / Auxiliary Market Outlook
3.2. Mapping of penetration and growth prospects
3.3. Industry value chain analysis
3.3.1. Reimbursement framework
3.4. Market dynamics
3.4.1. Market driver analysis
3.4.1.1. Increased prevalence of eye diseases
3.4.1.2. Technological advances
3.4.1.3. Government initiatives to increase awareness of the visually impaired
3.4.2. Analysis of market constraints
3.4.2.1. Risks associated with vitrectomy
3.5. Vitrectomy Devices Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Purchasing power
3.5.1.3. Threat of substitution
3.5.1.4. Threat of a new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. The political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Analysis of major transactions and strategic alliances
3.5.4. Market entry strategies

Chapter 4. Vitrectomy Devices Product Estimates and Trend Analysis
4.1. Definitions and scope
4.1.1. Vitrectomy machines
4.1.2. Vitrectomy packs
4.1.3. Photocoagulation lasers
4.1.4. Lightening devices
4.2. Product market share, 2020 and 2028
4.3. Segment dashboard
4.4. Global Vitrectomy Devices Market By Product Outlook
4.5. Market size and forecast and trend analysis, 2016 to 2028 for the following
4.5.1. Vitrectomy machines
4.5.1.1. Vitrectomy Machine Market Estimates & Forecasts 2016-2028 (USD Million)
4.5.2. Vitrectomy packs
4.5.2.1. Vitrectomy Packs Market Estimates & Forecasts 2016-2028 (Million USD)
4.5.3. Photocoagulation lasers
4.5.3.1. Photocoagulation Lasers Market Estimates & Forecasts 2016-2028 (USD Million)
4.5.4. Lightening devices
4.5.4.1. Lighting Devices Market Estimates & Forecasts 2016-2028 (USD Million)

Chapter 5. Vitrectomy Devices: Application Estimates and Trend Analysis
5.1. Definitions and scope
5.1.1. Diabetic retinopathy
5.1.2. Retinal detachment
5.1.3. Macular hole
5.1.4. Vitreous hemorrhage
5.1.5. Others
5.2. Application market share, 2020 and 2028
5.3. Segment dashboard
5.4. Global Vitrectomy Devices Market by Application Outlook
5.5. Market size and forecast and trend analysis, 2016 to 2028 for the following
5.5.1. Diabetic retinopathy
5.5.1.1. Diabetic Retinopathy Market Estimates & Forecasts 2016-2028 (USD Million)
5.5.2. Retinal detachment
5.5.2.1. Retinal Detachment Market Estimates & Forecasts 2016-2028 (USD Million)
5.5.3. Macular hole
5.5.3.1. Macular Holes Market Estimates & Forecasts 2016-2028 (USD Million)
5.5.4. Vitreous hemorrhage
5.5.4.1. Vitreous Hemorrhage Market Estimates & Forecasts 2016-2028 (USD Million)
5.5.5. Others
5.5.5.1. Other Market Estimates and Forecasts 2016 to 2028 (USD Million)

Chapter 6. Vitrectomy devices: end-use estimates and trend analysis
6.1. Definitions and scope
6.1.1. Hospitals
6.1.2. Ophthalmology clinics
6.1.3. Ambulatory surgery centers
6.2. End-use market share, 2020 and 2028
6.3. Segment dashboard
6.4. Global Vitrectomy Devices Market By End Use Outlook
6.5. Market size and forecast and trend analysis, 2018 to 2028 for the following
6.5.1. Hospitals
6.5.1.1. Hospital Market Estimates & Forecasts 2016-2028 (USD Million)
6.5.2. Ophthalmology clinics
6.5.2.1. Ophthalmology Clinics Market Estimates & Forecasts 2016-2028 (USD Million)
6.5.3. Outpatient surgery centers
6.5.3.1. Ambulatory Surgery Center Market Estimates & Forecasts 2016-2028 (USD Million)

Chapter 7. Vitrectomy Devices Market: Regional Estimates and Trend Analysis

Chapter 8. Competitive landscape
8.1. Recent developments and impact analysis, by the main market players
8.2. Categorization of companies / competitions
8.2.1. Innovators
8.2.2. Market leaders
8.2.3. Emerging players
8.3. Supplier landscape
8.3.1. List of main distributors and distribution partners
8.3.2. The main clients
8.3.3. Market share analysis of key companies, 2020
8.4. Public enterprises
8.4.1. Analysis of the company’s position in the market (revenues, geographic presence, product portfolio, key service industries, key alliances)
8.4.2. Market share / company ranking, by region
8.4.3. Competitive dashboard analysis
8.4.3.1. Market differentiators
8.4.3.2. Synergy analysis: major transactions and strategic alliances
8.5. Private companies
8.5.1. List of top emerging companies / technology disruptors / innovators
8.5.2. Funding prospects
8.5.3. Regional network map
8.5.4. Analysis of the company’s position in the market (geographic presence, product portfolio, key alliance, industry experience)
8.6. Supplier ranking
8.7. Key Company Profile
8.7.1. Alcon Inc.
8.7.1.1. Company presentation
8.7.1.2. Financial performance
8.7.1.3. Comparative analysis of products
8.7.1.4. Strategic initiatives
8.7.2. Bausch & Lomb Incorporated
8.7.2.1. Company presentation
8.7.2.2. Financial performance
8.7.2.3. Comparative analysis of products
8.7.2.4. Strategic initiatives
8.7.3. BVI
8.7.3.1. Company presentation
8.7.3.2. Financial performance
8.7.3.3. Comparative analysis of products
8.7.3.4. Strategic initiatives
8.7.4. NIDEK CO., LTD.
8.7.4.1. Company presentation
8.7.4.2. Financial performance
8.7.4.3. Comparative analysis of products
8.7.4.4. Strategic initiatives
8.7.5. Johnson & Johnson Vision Care, Inc.
8.7.5.1. Company presentation
8.7.5.2. Financial performance
8.7.5.3. Comparative analysis of products
8.7.5.4. Strategic initiatives
8.7.6. Flashing Medical
8.7.6.1. Company presentation
8.7.6.2. Financial performance
8.7.6.3. Comparative analysis of products
8.7.6.4. Strategic initiatives
8.7.7. Topcon Corporation
8.7.7.1. Company presentation
8.7.7.2. Financial performance
8.7.7.3. Comparative analysis of products
8.7.7.4. Strategic initiatives
8.7.8. Carl Zeiss Meditec SA
8.7.8.1. Company presentation
8.7.8.2. Financial performance
8.7.8.3. Comparative analysis of products
8.7.8.4. Strategic initiatives
8.7.9. Hoya surgical optics
8.7.9.1. Company presentation
8.7.9.2. Financial performance
8.7.9.3. Comparative analysis of products
8.7.9.4. Strategic initiatives

For more information on this report, visit https://www.researchandmarkets.com/r/azscym

Media contact:

Research and markets
Laura Wood, senior
press@researchandmarkets.com

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

Cision

Cision

Show original content:https://www.prnewswire.com/news-releases/insights-on-the-vitrectomy-devices-global-market-to-2028—featuring-blink-medical-topcon-and-carl-zeiss-meditec- among-others-301418462.html

SOURCE Research and Markets


Source link

]]>
Mandryk: The realities of COVID-19 are encroaching on Saskatchewan. legislative chamber https://web-xpress.com/mandryk-the-realities-of-covid-19-are-encroaching-on-saskatchewan-legislative-chamber/ Sat, 06 Nov 2021 13:07:06 +0000 https://web-xpress.com/mandryk-the-realities-of-covid-19-are-encroaching-on-saskatchewan-legislative-chamber/ Breadcrumb Links Chroniclers The pointlessness and insensitivity of the chamber are seldom lost on the public, especially those who have no choice but to interfere in it. Author of the article: Murray Mandryk On November 4, 2021, Premier Scott Moe listens in the Legislative Rotunda Dallas Oberik, 70, about his difficulties undergoing hip replacement surgery. […]]]>

The pointlessness and insensitivity of the chamber are seldom lost on the public, especially those who have no choice but to interfere in it.

Content of the article

There was a public apology inside the Saskatchewan Legislature this week, albeit timid for something inconsequential to the realities plaguing our province at this time.

Advertising

Content of the article

Welcome to your Saskatchewan legislative chamber – the place where we send our peers to solve our problems only to, invariably, see them so caught up in the games of the place that they forget why we sent them.

Fortunately, however, reality knocks on the bedroom door sometimes to remind them of this. It happened again this week.

First, the absurdity of our large room …

Government House Leader Jeremy Harrison on Wednesday called on President Randy Weekes to ask NDP MP Regina Elphinstone Meara Conway for using the official last name of Health Minister Paul Merriman because the The use of real names of politicians is prohibited by House rules.

Yes folks, your taxes at work – adult men and women childishly tease each other for breaking meaningless rules, like women wearing open-toed shoes, men not wearing ties, limbs having something else on their desk only properly sanctioned green coffee cups and, God forbid, calling people by their legal names instead of their temporary titles.

In fairness, the bedroom is an adult place that requires adult rules to function. And Conway may have been childishly irrelevant when she called Regina’s homeless and drug-addict tent city “Camp Merriman” as opposed to its proper name, Camp Marjorie.

Outside the chamber, the still articulate lawyer told reporters it was just a slip of the tongue, before adding that the current housing crisis for Saskatchewan income support recipients ( SIS) was the result of a change in policy under Merriman when he was Minister of Social Services.

Advertising

Content of the article

But what shouldn’t be lost in Conway’s possible irritation is his worry that humans are living in tents at the onset of a Saskatchewan winter. Shouldn’t members of Parliament apologize for this? Shouldn’t they apologize for a lot of things?

Graham Dickson, Laura Wiens and their one-year-old daughter Helen, whose struggles with suspected cerebral palsy have worsened, likely deserved an apology for COVID-19 delays that postponed baby’s eye surgery and MRI diagnoses .

Wheelchair-bound Dallas Oberik, 70, deserved an apology for her three-year wait for hip surgery, likely to be delayed a year and a half by the backlog COVID-19 has created in our hospitals.

And the families of 862 Saskatchewanians died of COVID-19 surely deserve an unequivocal apology from Prime Minister Scott Moe for not having policies that prevented this outcome.

Instead, the chamber provided us with a debate on the utterly unnecessary Throne Speech this week, inflammatory rhetoric from the official opposition about a government killing people and the obsequiousness of government members praising the prime minister as a “Rock star” for his management of COVID-19.

We even got the extra spectacle of now independent MP Nadine Wilson in her response in the Speech from the Throne telling us (without any evidence) that Saskatchewan families are fleeing to the United States, Korea, Nicaragua and Brazil. to avoid the Saskatchewan vaccination warrants that are now in effect. human rights monitoring (this is not the case). Wilson was throwing more Hail Mary at the anti-vax crowd than Green Bay Packers quarterback Aaron Rodgers – perhaps unsurprisingly, given that they seem to share the same vaccine disclosure policy.

Advertising

Content of the article

How unnecessary and insensitive the bedroom can be is rarely lost on the public – especially those with no choice but to interfere in it.

In a Twitter feed in motion, Graham Dickson wrote about the disrespect his family suffered in the chamber in which ruling politicians concerned about chamber games did not look or address his family. Dickson called Harrison “the dog that must bark every time a car passes.” It was fair and brilliant.

The only consolation is that politicians often suddenly become more human when confronted with the realities of the people.

It also happened in the Saskatchewan Legislature this week, but mainly in the rotunda just outside the chamber where Oberik spoke with Moe and Dickson, Wiens and Baby Helen met Merriman.

Perhaps much to the chagrin of those who just want to vilify the two, Moe and Merriman seemed genuinely moved by the stories. Both listened.

Maybe that won’t make a big difference in politics. But once again you got the impression that the people’s chamber would be better if we just heard from the people.

Mandryk is a political columnist for the Regina Leader-Post and the Saskatoon StarPhoenix.

News seems to fly to us faster all the time. From COVID-19 updates to politics and crime and everything in between, it can be hard to keep pace. With that in mind, the Regina Leader-Post has created an Afternoon Headlines newsletter that can be delivered to your inbox daily to make sure you’re up to date with the most important news of the day. Click here to subscribe.

Advertising

comments

Postmedia is committed to maintaining a lively but civil discussion forum and encourages all readers to share their views on our articles. Comments may take up to an hour of moderation before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread that you follow, or if a user that you follow comments. Visit our Community rules for more information and details on how to adjust your E-mail The settings.



Source link

]]>